These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 24754973)

  • 21. Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out.
    Citrome L
    Int J Clin Pract; 2014 Dec; 68(12):1401-5. PubMed ID: 25418525
    [No Abstract]   [Full Text] [Related]  

  • 22. Naltrexone/bupropion: an investigational combination for weight loss and maintenance.
    Makowski CT; Gwinn KM; Hurren KM
    Obes Facts; 2011; 4(6):489-94. PubMed ID: 22249001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists.
    Barrea L; Pugliese G; Muscogiuri G; Laudisio D; Colao A; Savastano S
    Minerva Endocrinol; 2020 Jun; 45(2):127-137. PubMed ID: 32643356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes.
    Hong K; Herrmann K; Dybala C; Halseth AE; Lam H; Foreyt JP
    Clin Obes; 2016 Oct; 6(5):305-12. PubMed ID: 27477337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.
    Ali KF; Shukla AP; Aronne LJ
    Expert Rev Clin Pharmacol; 2016; 9(1):27-34. PubMed ID: 26512740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder.
    Carbone EA; Caroleo M; Rania M; Calabrò G; Staltari FA; de Filippis R; Aloi M; Condoleo F; Arturi F; Segura-Garcia C
    Eat Weight Disord; 2021 Apr; 26(3):779-788. PubMed ID: 32356145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Naltrexone + bupropion (Mysimba). Too risky for only modest weight loss.
    Prescrire Int; 2015 Oct; 24(164):229-33. PubMed ID: 26594724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination?
    Citrome L
    Int J Clin Pract; 2010 Oct; 64(11):1462-1465. PubMed ID: 20846190
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacologic therapies for obesity.
    Kaplan LM
    Gastroenterol Clin North Am; 2010 Mar; 39(1):69-79. PubMed ID: 20202580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects.
    Wilcox CS; Oskooilar N; Erickson JS; Billes SK; Katz BB; Tollefson G; Dunayevich E
    Addict Behav; 2010 Mar; 35(3):229-34. PubMed ID: 19926400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity.
    Plodkowski RA; Nguyen Q; Sundaram U; Nguyen L; Chau DL; St Jeor S
    Expert Opin Pharmacother; 2009 Apr; 10(6):1069-81. PubMed ID: 19364254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'?
    Katsiki N; Hatzitolios AI; Mikhailidis DP
    Ann Med; 2011 Jun; 43(4):249-58. PubMed ID: 21254901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR.
    Drugs R D; 2010; 10(1):25-32. PubMed ID: 20509712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Putting the brakes on the "drive to eat": Pilot effects of naltrexone and reward-based eating on food cravings among obese women.
    Mason AE; Laraia B; Daubenmier J; Hecht FM; Lustig RH; Puterman E; Adler N; Dallman M; Kiernan M; Gearhardt AN; Epel ES
    Eat Behav; 2015 Dec; 19():53-6. PubMed ID: 26164674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial.
    Wharton S; Yin P; Burrows M; Gould E; Blavignac J; Christensen RAG; Kamran E; Camacho F; Barakat M
    Int J Obes (Lond); 2021 Aug; 45(8):1687-1695. PubMed ID: 34083744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2015 Jun; 53(6):19-22. PubMed ID: 26091546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial.
    Grilo CM; Lydecker JA; Fineberg SK; Moreno JO; Ivezaj V; Gueorguieva R
    Am J Psychiatry; 2022 Dec; 179(12):927-937. PubMed ID: 36285406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial.
    Grilo CM; Lydecker JA; Gueorguieva R
    Psychol Med; 2023 Dec; 53(16):7775-7784. PubMed ID: 37366017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Naltrexone/bupropion modifies weight, food intake, and Drd2 gene expression in rats.
    Roberto da Silva G; Carneiro MG; Barbosa MP; Costa JA; de Souza IA; Dos Santos Oliveira L; de Vasconcelos DAA; do Nascimento E; Matos RJB; Lopes de Souza S; de Freitas MFL
    J Endocrinol; 2022 Apr; 253(3):85-96. PubMed ID: 35302951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of combined naltrexone and bupropion therapy on the brain's functional connectivity.
    Wang GJ; Zhao J; Tomasi D; Kojori ES; Wang R; Wiers CE; Caparelli EC; Volkow ND
    Int J Obes (Lond); 2018 Nov; 42(11):1890-1899. PubMed ID: 29535451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.